Profile data is unavailable for this security.
About the company
Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company. The Company has a portfolio of therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. The Company's Neuroinnovation portfolio includes NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine and a pipeline of product candidates across five platforms: calcitonin gene related peptide (CGRP) receptor antagonism for the acute and preventive treatment of migraine as well as other pain-related disorders and non-migraine indications; glutamate modulation for obsessive-compulsive disorder (OCD); myeloperoxidase (MPO) inhibition for multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS); Kv7 Ion Channel Activators (Kv7) to target indications including epilepsy, pain disorders and effective disorders; and Myostatin offers a natural protein that limits skeletal muscle growth.
- Revenue in USD (TTM)859.68m
- Net income in USD-1.02bn
- Incorporated2013
- Employees928.00
- LocationBiohaven Pharmaceutical Holding Company Ltd215 Church StNEW HAVEN 06510-1803United StatesUSA
- Phone+1 (203) 404-0410
- Websitehttps://www.biohavenpharma.com/
More ▼
Mergers & acquisitions
| Acquired company | BHVN:NYQ since announced | Transaction value |
|---|---|---|
| Channel Biosciences LLC | 10.43% | 1.24bn |
Data delayed at least 15 minutes, as of Aug 12 2022 21:10 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TriNet Group Inc | 4.80bn | 377.00m | 5.37bn | 3.50k | 15.55 | 7.26 | 12.06 | 1.16 | 5.74 | 5.74 | 72.97 | 12.29 | 1.59 | -- | 14.28 | 1,713,571.00 | 12.52 | 8.52 | 25.92 | 21.87 | 21.95 | 19.13 | 7.86 | 6.00 | -- | 38.29 | 0.3935 | 0.00 | 12.54 | 8.21 | 24.26 | 40.65 | 0.00 | -- |
| Terminix Global Holdings Inc | 2.09bn | 66.00m | 5.44bn | 11.70k | 85.33 | 2.28 | 31.71 | 2.65 | 0.5351 | 0.5269 | 17.12 | 20.05 | 0.4626 | 28.53 | 9.95 | 178,974.40 | 1.39 | 0.6958 | 1.58 | 0.8061 | 40.74 | 43.22 | 3.01 | 1.84 | 1.20 | 5.57 | 0.2683 | 0.00 | 4.28 | -5.72 | 530.00 | -4.18 | -17.04 | -- |
| FTI Consulting, Inc. | 2.86bn | 218.44m | 5.58bn | 7.05k | 26.40 | 3.43 | 21.18 | 1.96 | 6.14 | 6.14 | 80.22 | 47.21 | 0.9617 | -- | 3.26 | 421,396.90 | 7.35 | 6.81 | 9.09 | 8.64 | 31.06 | 32.90 | 7.65 | 7.66 | -- | 43.05 | 0.1616 | 0.00 | 12.80 | 8.93 | 11.53 | 22.40 | 18.87 | -- |
| ExlService Holdings, Inc. | 1.26bn | 126.83m | 5.73bn | 37.40k | 46.97 | 8.47 | 32.35 | 4.59 | 3.73 | 3.73 | 37.11 | 20.70 | 1.03 | 326.23 | 5.96 | 33,738.07 | 10.28 | 7.67 | 12.73 | 9.58 | 37.38 | 35.34 | 10.03 | 8.64 | 2.10 | -- | 0.2939 | 0.00 | 17.10 | 10.35 | 28.26 | 13.20 | 7.58 | -- |
| Cerevel Therapeutics Holdings Inc | 0.00 | -279.88m | 5.91bn | 200.00 | -- | 13.56 | -- | -- | -1.90 | -1.90 | 0.00 | 3.05 | 0.00 | -- | -- | 0.00 | -56.68 | -- | -62.08 | -- | -- | -- | -- | -- | -- | -- | 0.1073 | -- | -- | -- | -51.97 | -- | -- | -- |
| Western Union Co | 4.87bn | 888.80m | 6.28bn | 10.50k | 7.38 | 14.21 | 5.89 | 1.31 | 2.23 | 2.23 | 12.23 | 1.16 | 0.5477 | -- | -- | 463,342.80 | 10.01 | 8.23 | 12.16 | 10.34 | 43.61 | 41.09 | 18.27 | 14.27 | -- | 23.15 | 0.8574 | 47.09 | 4.88 | -1.33 | 8.26 | 26.05 | -2.65 | 7.99 |
| WEX Inc | 2.10bn | 193.45m | 7.26bn | 5.60k | 38.76 | 4.07 | 14.77 | 3.50 | 4.28 | 4.28 | 45.83 | 40.79 | 0.1945 | -- | 0.5717 | 374,298.90 | 2.09 | 0.7327 | 3.49 | 1.11 | 62.34 | 62.43 | 10.77 | 3.54 | -- | 8.63 | 0.6179 | 0.00 | 18.63 | 12.82 | 100.06 | -64.26 | 6.84 | -- |
| Robert Half International Inc | 7.16bn | 682.88m | 8.52bn | 14.60k | 12.98 | 5.98 | 11.98 | 1.22 | 6.17 | 6.17 | 64.68 | 13.39 | 2.52 | -- | 7.16 | 490,420.80 | 24.07 | 19.37 | 42.52 | 33.14 | 42.69 | 41.13 | 9.54 | 7.42 | -- | 13.55 | 0.00 | 32.84 | 26.47 | 4.24 | 95.45 | 11.76 | -15.09 | 11.55 |
| Genpact Ltd | 4.25bn | 343.32m | 8.76bn | 109.60k | 26.60 | 5.01 | 18.46 | 2.08 | 1.80 | 1.80 | 22.23 | 9.54 | 0.8996 | -- | 4.35 | 38,737.26 | 7.27 | 7.58 | 9.66 | 10.04 | 35.07 | 35.81 | 8.09 | 9.03 | -- | 12.73 | 0.4723 | 21.02 | 8.43 | 9.37 | 19.84 | 6.50 | -8.40 | -- |
| Sarepta Therapeutics Inc | 835.18m | -506.63m | 9.55bn | 840.00 | -- | 13.62 | -- | 11.86 | -5.87 | -5.87 | 9.81 | 8.30 | 0.2902 | 0.5219 | 5.04 | 994,266.70 | -17.60 | -22.01 | -21.17 | -25.20 | 85.10 | 87.56 | -60.66 | -101.07 | 4.14 | -8.14 | 0.6025 | -- | 29.96 | 164.51 | 24.43 | -- | 41.17 | -- |
| Nielsen Holdings PLC | 3.54bn | 570.00m | 9.90bn | 14.00k | 17.34 | 2.84 | 8.98 | 2.79 | 1.58 | 1.47 | 9.80 | 9.65 | 0.3222 | -- | 6.90 | 252,500.00 | 5.31 | 1.30 | 5.78 | 1.50 | 63.68 | 60.63 | 16.46 | 4.10 | -- | 3.52 | 0.6054 | 170.37 | 4.14 | -11.12 | 190.00 | 1.88 | -4.66 | -27.64 |
| Biohaven Pharmaceutical Holding Co Ltd | 859.68m | -1.02bn | 10.53bn | 928.00 | -- | -- | -- | 12.23 | -14.82 | -14.82 | 12.60 | -11.26 | 0.7703 | 1.45 | 3.30 | 926,383.60 | -83.39 | -124.44 | -167.93 | -194.74 | 85.63 | -- | -108.26 | -477.81 | 1.59 | -2.38 | 2.53 | -- | 626.91 | -- | -10.41 | -- | 131.21 | -- |
| R1 RCM Holdco Inc | 1.56bn | 62.00m | 10.70bn | 10.20k | 127.18 | 3.94 | 73.43 | 6.96 | 0.2048 | 0.2048 | 5.13 | 6.62 | 0.4966 | -- | 6.92 | 152,568.60 | 1.98 | 3.82 | 2.19 | 4.90 | 21.91 | 16.98 | 3.98 | 3.06 | -- | 5.29 | 0.3943 | -- | 16.04 | 20.00 | -1,144.52 | -- | 32.55 | -- |
| Booz Allen Hamilton Holding Corporation | 8.62bn | 509.32m | 12.67bn | 29.30k | 25.26 | 11.60 | 18.97 | 1.48 | 3.81 | 3.81 | 64.42 | 8.29 | 1.44 | -- | 4.93 | 294,342.50 | 8.58 | 9.99 | 11.32 | 13.76 | 53.48 | 53.76 | 5.94 | 6.13 | -- | 8.26 | 0.7169 | 33.84 | 6.42 | 7.56 | -23.42 | 12.39 | 8.20 | 19.96 |
Data as of Aug 12 2022. Currency figures normalised to Biohaven Pharmaceutical Holding Company Ltd's reporting currency: US Dollar USD
33.72%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2022 | 4.17m | 5.87% |
| Capital Research & Management Co. (World Investors)as of 31 May 2022 | 3.45m | 4.85% |
| 1919 Investment Counsel LLCas of 31 Mar 2022 | 3.05m | 4.29% |
| Janus Henderson Investors US LLCas of 31 Mar 2022 | 2.69m | 3.79% |
| Marshall Wace LLPas of 31 Mar 2022 | 2.40m | 3.38% |
| Oracle Investment Management, Inc.as of 31 Mar 2022 | 2.06m | 2.90% |
| SSgA Funds Management, Inc.as of 31 Mar 2022 | 1.66m | 2.33% |
| Eventide Asset Management LLCas of 31 Mar 2022 | 1.64m | 2.30% |
| Capital Research & Management Co. (International Investors)as of 31 May 2022 | 1.57m | 2.21% |
| The Vanguard Group, Inc.as of 30 Jun 2022 | 1.29m | 1.82% |
More ▼
Data from 31 Mar 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
